Cancer is a major health issue worldwide, and the global burden of cancer is expected to
increase in the coming years. Whereas the limited success with current therapies has driven …

Leflunomide is a selective inhibitor of de novo pyrimidine synthesis. In phase II and III
clinical trials of active rheumatoid arthritis, leflunomide was shown to improve primary and …

Background Phase II trials of leflunomide, an inhibitor of de-novo pyrimidine synthesis, have
shown efficacy in rheumatoid arthritis. This double-blind randomised trial compared …

Leflunomide (Arava) has recently been approved by the Food and Drug Administration for
the treatment of rheumatoid arthritis (RA). This approval was based on data from a double …

Proper nucleosides availability is crucial for the proliferation of living entities (eukaryotic
cells, parasites, bacteria, and virus). Accordingly, the uses of inhibitors of the de novo …

Thousands of organs are transplanted each year and millions of people suffer from
autoimmune diseases, which creates a need for an armamentarium of immunosuppressive …

Leflunomide (Arava™) has recently been approved by the Food and Drug Administration for
the treatment of rheumatoid arthritis (RA). The drug, due to its protective effects on structural …

The mode of action of Leflunomide, an immunomodulatory drug used in rheumatoid arthritis,
is debated. This study, using 14 C-labeled de novo purine and pyrimidine synthesis …

Leflunomide is a novel immunosuppressive and antiinflammatory agent currently being
tested for treatment of autoimmune diseases and transplant rejection. NF-κB is a …

Background. Polyoma BK virus produces an aggressively destructive nephropathy in
approximately 3% to 8% of renal allografts, is associated with graft loss within one year in …